Most material SEC filings — August 12, 2026

Equity Residential and AvalonBay Communities shareholders approved a merger of equals on August 12, 2026, with closing expected August 17, 2026. Each AvalonBay share converts to 2.793 Equity Residential shares; the combined entity will trade as Vivmark Residential (VMRK) on NYSE, combining 312 EQR properties (85,520 units) with 322 AVB properties (99,072 units) for ~184,592 total apartment units across major U.S. metros. Over 99% shareholder approval at both companies, representing approximately 90% of outstanding shares at each.

AvalonBay Communities and Equity Residential have received shareholder approvals (>99% votes cast, ~90% shares outstanding) for their merger of equals. AvalonBay shareholders will receive 2.793 Equity Residential shares per share held. The combined entity, Vivmark Residential, will trade on NYSE under ticker VMRK starting August 18, 2026, with closing expected August 17, 2026.

Hashdex Asset Management announced closure and liquidation of the Hashdex Bitcoin ETF (NYSE Arca: DEFI), a $14.7M fund as of July 30, 2026. The sole series of Hashdex Commodities Trust will cease trading August 17, 2026, begin asset liquidation August 18, 2026, and distribute remaining net assets to shareholders on or about August 24, 2026. The sponsor cited low AUM relative to operating expenses as the reason for termination.

On June 25, 2026, Bio-Techne agreed to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. The transaction was announced during the company's Q4 FY2026 earnings (ended June 30, 2026), in which Bio-Techne reported flat full-year revenue of $1.2 billion, GAAP EPS of $1.16 (vs. $0.46 prior year), and adjusted EPS of $1.93 (flat vs. $1.92 prior year). Bio-Techne has ceased holding investor conference calls due to the pending transaction.

ENvue Medical (market cap ~$7.3M) entered into two agreements on August 12, 2026: (1) a Common Shares Purchase Agreement with an unnamed Liechtenstein-based investor, providing up to $50M in committed capital through a variable-price VWAP mechanism (limited to 19.99% of shares outstanding absent shareholder approval); and (2) a Second Amendment to its Series H Preferred Stock purchase agreement, extending the Preferred Holders' additional investment rights by 36 months with a mandatory $10M annual minimum (reduced dollar-for-dollar by proceeds from the ELOC or Form S-3 shelf). The company commits 40% of registered offering proceeds to redeem outstanding Series X Preferred Stock.

CID HoldCo (DAIC) received a delisting notice from Nasdaq on August 6, 2026, for failing to maintain the $50M minimum market value of listed securities (MVLS) requirement. The company has announced intention to appeal by requesting a hearing before a Nasdaq Hearings Panel (by August 13, 2026 deadline with $20,000 fee); the stock remains listed pending the hearing outcome. The company previously regained compliance with the minimum bid price requirement ($1.00+) on June 23, 2026, but failed to regain MVLS compliance by the August 4 deadline.

MODIV Industrial filed an 8-K on 2026-08-12 disclosing Item 1.02 (termination of material definitive agreement), Item 2.01 (completion of acquisition or disposition of assets), Item 3.01 (delisting/listing transfer notice), Item 3.03 (security holder rights modification), Item 5.01 (change in control), Item 5.02 (director/officer departures and compensation changes), and Item 5.03 (charter/bylaw amendments). The filing references 12 documents but the actual agreement terms, counterparties, dollar amounts, share counts, and specific dates of these transactions are not disclosed in this document index—only item headers are present.

On August 6, 2026, Generation Income Properties, Inc. (GIPR) received notice of delisting or failure to satisfy continued listing standards from its exchange. The 8-K filing on August 12, 2026 discloses Item 3.01 regarding this delisting notice and transfer of listing. No specific remediation timeline, financial metrics, or counterparty details are provided in the filing header.

Lulu's Fashion Lounge (market cap ~$2.9M) entered a Purchase Agreement with ARC Group International Ltd. dated August 11, 2026, for a $4.5M equity line of credit. The Investor may purchase up to $4.5M of common stock on demand via periodic advances (max $2.25M per advance, 75% of 10-day avg daily value traded). Investor receives ~$200K in commitment fee shares (valued at average VWAP for 10 days prior to signing). Company must file registration statement within 45 days and maintain effectiveness. 36-month term or until $4.5M drawn, whichever first. Investor capped at 4.99% ownership; shares priced at 96% (regular) or 90% (rapid) of VWAP.

XMax Inc. agreed to purchase 561,426 ordinary shares of Aerora Technology Co., Ltd. from Cobalt Pacific Holdings Ltd. for US$12,003,287.95 (US$21.38 per share) under a Securities Purchase Agreement dated August 10, 2026, with closing by August 31, 2026. The transaction requires compliance with Aerora's Amended Restated Investors Rights Agreement (including right-of-first-refusal provisions) and represents a ~4% stake relative to Aerora's 14,035,650 outstanding shares.

Southland reported Q2 2026 revenue of $113.3M (down 47% YoY from $215.4M) and a gross loss of $71.2M (vs. $13M gross profit YoY), driven by a $93.6M negative cumulative catch-up adjustment on legacy contract claims and modifications. Net loss reached $84.3M ($1.55/share) vs. $10.3M YoY. Gross margin collapsed to (62.9)% from 6.0%. The company holds $1.68B backlog but faces material liquidity pressure with cash of $34.9M (down from $52.7M at year-end) and surety payables of $298.9M (nearly 5x the year-end balance).

Workhorse Group (WKHS) amended its cash flow credit agreement with Motive GM Holdings II LLC on August 11, 2026, increasing the credit commitment from $30M to $40M (+$10M). As consideration, Workhorse issued warrants to purchase 750,000 shares at $10/share for Amendment No. 2 loans, plus an additional 750,000 shares at $10/share for the new Amendment No. 3 loans (1.5M shares total). The lender's obligation to fund post-closing is discretionary, not binding. Interest on the new $20M tranche defers until after January 31, 2027.

Mobilewalla Holdco, Inc. and SPACSphere Acquisition Corp. (NASDAQ: SSAC) filed a Form S-4 registration statement with the SEC for their proposed business combination. The combined company will operate as Covariate, Inc. and trade on Nasdaq. The transaction, subject to shareholder approval and SEC effectiveness, is expected to close in H2 2026. No specific valuations, share counts, or transaction dollar amounts are disclosed in this filing.

Cycurion, Inc. (NASDAQ: CYCU) announced its hearing before the Nasdaq Hearings Panel is scheduled for August 20, 2026, at 10:00 a.m. ET. The company's stock remains listed and trading on Nasdaq Capital Market under symbol CYCU; the timely hearing request stayed delisting action pending the Panel's final written decision. No specific compliance violations, financial figures, or remediation details were disclosed in this update.

On August 7, 2026, Capstone Holding Corp. (public market cap ~$1.4M) filed an 8-K disclosing Item 4.02: non-reliance on previously issued financial statements or audit report. No specific dollar amounts, restatement details, affected periods, or root causes are stated in the filing header or document list provided. The filing references XBRL exhibits but those substantive details are not included in this excerpt.

Arbutus received $178.4M in July 2026 as its share of a $950M noncontingent settlement from Moderna (with potential $1.3B contingent payment pending appellate ruling). The company plans to return up to $230M to shareholders via buybacks starting Q3 2026. Additionally, Arbutus filed three international patent lawsuits against Pfizer/BioNTech over LNP technology, and achieved FDA alignment on imdusiran Phase 2b trial design for chronic hepatitis B.

Splash Beverage Group (NYSE American: SBEV, market cap ~$6.5M) announced on August 12, 2026, that it will rebrand to Endovia Health Sciences effective August 24, 2026, with new ticker symbol EDVA. The pivot shifts the company from legacy beverage to a cannabinoid health sciences platform with three stated divisions: commercial pharmaceutical assets, FDA-regulated human/veterinary therapeutics, and consumer wellness beverages. The filing names Interim CEO Brady Cobb and references prior acquisitions of pharmaceutical IP and international partnerships over the past six months, but discloses no specific deal amounts, share counts, or financial metrics.

CVD Equipment completed the divestiture of its SDC division on April 1, 2026 for $17.4 million, generating net cash proceeds of approximately $15.0 million after transaction costs and taxes. The transaction resulted in a $13.9 million gain on discontinued operations. The company ended Q2 2026 with $23.5 million in cash, no long-term debt, and stockholders' equity of $36.0 million, up from $24.7 million at year-end 2025. However, continuing operations show weakness: revenue declined 42.6% year-over-year to $2.0 million, orders fell to $1.2 million, backlog decreased to $3.9 million, and the company reported a $1.4 million net loss from continuing operations. Post-quarter, a customer with an $0.8 million system order filed Chapter 11 bankruptcy.

Outlook Therapeutics reported net losses of $62.4M (FY2025) and $75.4M (FY2024). LYTENAVA generated only $1.4M revenue in FY2025 from Germany/UK launches; US commercial launch not yet commenced (FDA approval July 2026). Cash position of $7.7M (March 31, 2026) plus $4.2M (April offering) and $4.9M (May offering) estimated sufficient only through September 2026. Company carries $19.8M debt (Atlas note, 9.5% minimum, 7.5% exit fee, redeemable starting Sept 2026). Substantial doubt about going concern. Company is entirely dependent on LYTENAVA commercialization success with limited operating history and no prior drug commercialization experience.

On June 29, 2026, Decoy Therapeutics Inc. issued three series of warrants (A, B, C) to Armistice Capital Master Fund Ltd., totaling 2,961,085 common shares exercisable at $5.91/share. Series A: 592,217 shares (milestone: Phase 1 CTA filing in EEA); Series B: 1,184,434 shares (milestone: Phase 2a UK trial MHRA approval); Series C: 1,184,434 shares (milestone: Phase 2a primary endpoint announcement). All expire June 29, 2031 or 90 days post-milestone, whichever is earlier. Exercise contingent on stockholder approval.

10% owner CASCADE INVESTMENT, L.L.C. (RSG) bought 502K shares (~$108.1M) on the open market (0.4% of holdings). Open-market insider purchase — historically a bullish signal.

Solidion closed a $35M private placement on June 9, 2026, issuing 750,000 common shares and pre-funded warrants for 1,583,000 shares to an institutional investor at above-market price. The capital infusion raised cash from $0.2M (Dec 31, 2025) to $27.7M (June 30, 2026), eliminating previously disclosed substantial doubt about going-concern status. Additionally, long-term investors Madison Bond LLC and Bayside Project LLC converted their Series C and D pre-funded warrants into common stock with lock-up agreements, eliminating derivative liabilities and strengthening the balance sheet.

Direct Digital Holdings reported Q2 2026 revenue of $7.8M (down 23% YoY from $10.1M), driven by $2.5M loss in DSP customer spending. Excluding DSP, core revenue grew 3%. The company reported net loss of $3.6M (vs. $4.2M prior year), operating loss of $2.9M, and held only $0.52M cash as of June 30, 2026 (vs. $0.73M end-2025). Critically, management disclosed non-compliance with financial covenants on its credit facility and is seeking a waiver. Stockholders' deficit widened to $(13.8)M from $(7.0)M.

10% owner DART KENNETH BRYAN (FLUT) bought 150K shares (~$14.2M) on the open market (0.7% of holdings). Open-market insider purchase — historically a bullish signal.

Director MALONE JOHN C (GLIBK) bought 542K shares (~$13.6M) on the open market (17% of holdings). Open-market insider purchase — historically a bullish signal.

Director RECHTSCHAFFEN ANDREW (PNAQ) bought 1.2M shares (~$12.3M) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.

Chief Executive Officer Hudson Steven Kenneth (PNAQ) bought 1.5M shares (~$14.8M) on the open market (54% of holdings). Open-market insider purchase — historically a bullish signal.

In July 2026, AEON Biopharma closed an underwritten public offering generating $13.6M net upfront proceeds, plus up to $34.0M in gross proceeds upon exercise of milestone warrants. The company holds exclusive U.S. therapeutic rights to ABP-450, a proposed BOTOX® biosimilar. Cash runway extends to Q1 2027. AEON received FDA Type 2a feedback (January 2026) supporting its analytical strategy and expects Type 2b feedback in H2 2026 on clinical study requirements. As of June 30, 2026, cash was $3.4M; post-offering total is ~$17.0M against an $8.7M market cap.

OLB Group, Inc. (market cap ~$4.1M) entered into an Equity Distribution Agreement with Maxim Group LLC on August 7, 2026, to sell up to $1,600,000 of common stock at-the-market on the Nasdaq Capital Market. Maxim will act as sales agent, earning a 3.0% commission on gross proceeds. The offering is registered under Form S-3 (File No. 333-280347), initially effective July 2, 2024, with prospectus supplement dated August 7, 2026. No specific number of shares or pricing details are disclosed in this legal/distributor agreement document.

Hyperion DeFi (NASDAQ: HYPD), a $50.1M market-cap DeFi company, reported Q2 2026 net income of $31.0M (vs. $8.8M in Q1 2026) and Adjusted EBITDA of $53.7M (vs. $19.5M Q1). Core operating gross profit rose 20% QoQ to $1.15M. The company holds 2.04M HYPE tokens (up 56% since June 2025) valued at $132.6M, and redeployed 1M HYPE tokens into new partnerships with Entropy (HIP-3) and Skew (HIP-4), replacing 800K tokens freed from the USDH sunset. The company sold all legacy biotech IP to Arctic Vision and reiterated full-year 2026 guidance of $5-7M Adjusted Gross Profit (~5× 2025 FY results).

Fusemachines and Brazilian firm Qintess Holding signed a Master License and Services Agreement (effective August 10, 2026) with a $6.5M minimum committed services spend over three years. Fusemachines will issue up to 1,250,000 common shares to Qintess in three tranches: 750,000 shares immediately (Tranche 1); 250,000 shares at year 2 if $4.5M spent (Tranche 2); 250,000 shares at year 3 if full $6.5M spent (Tranche 3). Agreement includes prepayment milestones (min. $500K by 6 months, $1M by 12 months, $2M by 24 months) and registration rights requiring S-1 filing within 60 days.

On November 11, 2025, Richmond Mutual Bancorporation agreed to acquire The Farmers Bancorp (north-central Indiana lender, $1.125B assets as of March 31, 2026) in an all-stock transaction. Exchange ratio: 3.40 Richmond Mutual shares per Farmers share. Merger closed July 1, 2026. Purchase price ~$100.2M based on Richmond Mutual's $15.88 stock price on June 30, 2026. Combined pro forma assets ~$2.65B. Estimated merger costs: $12.5M pre-tax (~$9.9M after tax), including $3.85M professional fees, $4.73M data processing/conversion, and change-of-control payments of $1.83M.

Greenland Energy Co received notice from JV partner 80 Mile plc that the Government of Greenland has determined the project requires more extensive regulatory review than initially expected. The targeted permit timeline has been pushed from an unspecified earlier date to winter 2027. The company states it will use the delay to refine planning and logistics for its Jameson Land Basin onshore drilling campaign, with further updates to shareholders forthcoming.

Liquidia reported Q2 2026 net product sales of $170.4M (up 31% QoQ), net income of $74.7M, and adjusted EBITDA of $96.3M—the fourth consecutive quarter of rising profitability. As of July 31, 2026, ~5,900 unique prescriptions and 5,000+ patients started treatment since YUTREPIA launch in June 2025; >1,100 prescribers active, 30% with ≥5 referrals each. Cash increased $61.4M to $284.2M in Q2. Company is advancing 10 clinical studies for YUTREPIA and investigational L606 across PAH, PH-ILD, and new indications.

Fervo Energy completed its IPO in May 2026, raising approximately $2.2 billion in gross proceeds (including full over-allotment exercise). The company reported Q2 2026 net loss of $55.9 million and operating loss of $28.7 million, with capex of $226.5 million in Q2 and guidance of $850–$900 million for H2 2026. Fervo raised its long-term development target by 100 megawatts to 1.1 gigawatts by 2030, advanced Cape Station Phase I toward commercial operation (GeoBlock 1 first power targeted Q4 2026), and set a company drilling record with the Sawtooth 7 well.

On August 10, 2026, Capstone Holding Corp. reduced the conversion price of senior secured convertible notes held by 3i, LP from multiple prior prices ($0.75, $0.57, $1.10) to a uniform $0.2949 effective immediately. The adjustment applies to $250,372 principal under the July 2025 Note and $1,650,388 principal under the October 2025 Note, making conversion significantly more attractive to the investor. Additionally, the company granted 2.8M+ restricted shares to six executives under a new 2025 Stock Incentive Plan with base dilution protection provisions extending through March 2031.

On May 18, 2026, Beacon Bank Trust waived noncompliance by TotalStone LLC and related subsidiaries (Northeast Masonry Distributors, TotalStone Properties, CS Purchase Holdings, Carolina Stone Holdings, Carolina Stone Distributors) with the Cash Flow Coverage Ratio covenant for the 12-month period ending March 31, 2026, in exchange for a $7,000 noncompliance fee. The underlying Revolving Credit, Term Loan and Security Agreement originated December 20, 2017 and was most recently amended on December 19, 2025.

Altimmune announced initiation of the global PERFORMA Phase 3 trial in MASH (metabolic dysfunction-associated steatohepatitis) with 52-week data expected in 2029, positive topline results from the RECLAIM Phase 2 trial in alcohol use disorder showing statistically significant reduction in heavy drinking days, and completion of patient enrollment in the RESTORE Phase 2 trial in alcohol-associated liver disease. The company holds $519 million in cash, cash equivalents, and investments as of June 30, 2026, bolstered by a $225 million gross proceeds public offering completed in April 2026. Q2 2026 net loss was $22.8 million (vs. $22.1 million in Q2 2025); R&D expenses were $18.7 million.

Definium announced positive topline results from the Phase 3 Voyage study of DT120 ODT (lysergide 100 µg) in generalized anxiety disorder (n=214, 1:1 randomization vs. placebo). Primary endpoint: HAM-A score improved 5.4 points more than placebo at Week 12 (p<0.0001, Cohen's d=0.81). All key secondary endpoints also met. Safety profile consistent with prior studies; no new safety signals, no suicidality signal. This is Definium's second positive Phase 3 readout (first was Emerge in MDD in June). Panorama Phase 3 results in GAD expected September 2026.

FlyExclusive reported Q2 2026 consolidated revenue of $111 million (+22% YoY) with $4.2 million positive Adjusted EBITDA (vs. negative in prior year), a $9.4M sequential improvement from Q2 2025. The company reduced its fleet by 6% while increasing flight hours 8%, eliminated 32 non-performing aircraft, improved dispatch availability by 1,013 basis points, and reduced long-term notes payable by $94 million since 2024. Gross margin expanded 539 basis points to 20%, and Adjusted EBITDA margin improved 954 basis points YoY.

NeOnc Technologies (NTHI; $67.9M market cap) announced positive Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma (24 patients, intent-to-treat). Primary endpoint met: 6-month progression-free survival 48.9% (95% CI 26.3–68.1) vs pre-specified 20% standard-of-care benchmark (p=0.0047, one-sided). Median overall survival 26.09 months from recurrence (vs historical 6–9 month salvage benchmark); 86.7% alive at 6 months, 60.9% at 12 months. Five of 24 patients remain on treatment; no major toxicities reported. Company plans Type B FDA meeting to align on registrational (Phase 3) path.

Dyadic reported Q2 2026 revenue of $961,138 (down 0.6% YoY) and net loss of $2,123,884 ($0.06 per share). Cash declined 44% from $8.6M (Dec 2025) to $4.8M (June 2026). The company announced initial product shipments across recombinant proteins, partnerships with Proliant Health Biologicals, Fermbox Bio, and Inzymes, and Gates Foundation-funded antibody programs, but management disclosed substantial doubt about going-concern status for 12 months post-June 30, 2026.

Spruce Biosciences raised $5.5M via private stock purchase (Regulation D Rule 506(b)) from Cure Sanfilippo Foundation and National MPS Society (unspecified amounts per purchaser; Exhibit A redacted). Adrian Quartel hired as Chief Medical Officer effective July 27, 2026, at $512,300 annual base salary plus 40% target bonus and 13,000 RSU award vesting over four years. Proceeds designated exclusively for expanded-access enzyme replacement drug substance and product manufacturing.

On July 22, 2026, Monopar initiated a rolling NDA submission to the FDA for ALXN1840 (tiomolibdate choline) for Wilson disease treatment, with completion expected within months. The candidate received Rare Pediatric Disease designation on June 30, 2026, potentially qualifying for a Priority Review Voucher upon approval. Q2 2026 net loss was $5.3M ($0.62/share) vs. $2.5M ($0.35/share) in Q2 2025; cash position was $134.3M as of June 30, 2026, with runway through at least December 31, 2027.

Natural Gas Services Group completed the acquisition of Flatrock for approximately $119M ($108.9M cash + $10M stock) in June 2026, adding ~87,000 rented horsepower and materially increasing electric motor drive capabilities (20% vs. 7% pre-acquisition). Q2 2026 saw record results: rental revenue $49.4M (+25% YoY), adjusted EBITDA $25.1M (+27.4% YoY), and 88.3% horsepower utilization. Full-year 2026 adjusted EBITDA guidance raised from $92.5-97.5M to $103-108M; growth CapEx raised to $60-80M. Leverage at quarter-end was 2.77x with $172M unused commitments.

Intellinetics amended its 2024 Equity Incentive Plan to increase total shares reserved from 243,122 to 771,557 shares (a 217% increase) and its 2023 Non-Employee Director Compensation Plan from 150,000 to 302,863 shares (a 102% increase), both effective April 30, 2026, subject to shareholder approval. Combined, these amendments reserve 1,074,420 additional shares for future grants. No specific grants, recipients, or vesting schedules are disclosed in this amendment.

ABVC BioPharma, Inc. (ABVC), a Nevada corporation, entered into a Separation and Distribution Agreement dated June 22, 2026, with its wholly-owned subsidiary BioKey (Cayman), Inc. to effect a spin-off. ABVC will distribute 10% of BioKey's ordinary shares to ABVC shareholders on a pro rata basis (Record Date and Distribution Date to be determined by ABVC's Board), while retaining 90% ownership and control. The distribution is contingent on Form 10 SEC clearance, information statement delivery, required governmental approvals, and Board authorization; Parent (ABVC) retains unilateral termination rights until Effective Time.

Knightscope reported Q2 2026 revenue of $9.0 million, up 228% YoY from $2.7 million in Q2 2025, marking its second consecutive record quarter. The company achieved positive gross margin of $0.7 million (7% of revenue) versus a gross loss of $0.9 million in the prior-year period, driven by the Security Force acquisition. However, net loss widened to $14.1 million ($0.79/share) from $6.3 million ($0.90/share) YoY due to $13.8 million operating expenses; cash balance stood at $8.2 million at quarter-end.

Talphera's NEPHRO CRRT Phase 3 clinical study for nafamostat is 75% enrolled (expected completion by year-end 2026). The 2026 KDIGO Clinical Practice Guidelines added nafamostat as an acceptable regional anticoagulant for continuous renal replacement therapy—a positive regulatory signal versus prior guidance. Updated market research estimates ~200,000 annual U.S. CRRT procedures in 2027, up 21% from prior estimates. As of June 30, 2026, Talphera held $17.1M in cash and investments; Q2 2026 net loss was $4.3M ($0.06 per share) on $3.9M combined R&D and SG&A expenses.

Cerebras raised $6.4B gross in IPO (closed Q2) and secured $850M revolving credit facility. Core cloud revenue grew 287% YoY to $127.7M; core total revenue doubled to $209.9M. Company now has 600 MW data center capacity under contract, manufacturing capacity to scale >10x in 2026, and $25.4B remaining performance obligations. Partnerships with OpenAI (GPT-5.6 Sol at 750 tokens/sec), AWS, AMD, and CrowdStrike. Signed new customers Cognition and Lovable. Despite 103% core revenue growth, company posted $464.5M GAAP net loss H1 2026 (vs. $285.6M gain H1 2025) due to massive OpEx increase ($604M vs. $159M YoY) and $918M stock-based compensation. Full-year 2026 core revenue guidance raised to $880–890M.